Abstract
We focused on the differences in molecular mechanisms in the early stages of endometriosis-associated ovarian endometrioid carcinoma (OEMCa) and ovarian clear cell carcinoma (OCCCa).
Alterations in the β-catenin and PIK3CA genes, as well as expression of their associated markers, were investigated.
Mutations in exon 3 of the β-catenin gene were identified in 21 (60%) of 35 OEMCas. The mutations were also detected in the coexisting nonatypical (52.4%) and atypical (73.3%) endometriosis, and the single-nucleotide substitutions were identical in most cases. In contrast, the mutations were not identified in any of the OCCCas and their coexisting endometriosis. PIK3CA mutations were observed in 11 (31.4%) of 35 OEMCas and 10 (35.7%) of 28 OCCCas. Ten of 11 OEMCas had PIK3CA mutations in exon 9, and eight of 10 OCCCas had them in exon 20. The same mutations were also detected in the coexisting nonatypical and/or atypical endometriosis in three OEMCas and four OCCCas. In addition, significant differences in the expression of pAkt, hepatocyte nuclear factor 1β, hypoxia-inducible factor 1α, p65, and inducible nitric oxide synthase were evident between the two types of tumors and their coexisting endometriosis.
Distinct molecular events may occur in relatively early stages of tumorigenesis of endometriosis-associated OEMCas and OCCCas.
摘要
我们专注于子宫内膜异位症相关卵巢子宫内膜样癌(OEMCa)和卵巢透明细胞癌(OCCCa)早期阶段分子机制的差异。
我们研究了β-catenin和PIK3CA基因及其相关标志物表达的改变。
21/35例(60%)OEMCa检测到β-catenin基因3号外显子突变。这种突变也见于共存的无异型性(52.4%)和伴异型性(73.3%)的子宫内膜异位症,大部分病例替换的单核苷酸是相同的。相反,OCCCa及其共存的子宫内膜异位症均无一检测出该突变。PIK3CA突变见于11/35例(31.4%)OEMCa和10/28例(35.7%)OCCCa。10/11的OEMCa为PIK3CA9号外显子突变,8/10的OCCCa为20号外显子突变。3例OEMCa和4例OCCCa共存的无异型性和/或伴异型性的子宫内膜异位症也可检测到相同的突变。此外,这两种类型肿瘤及其共存的子宫内膜异位症在pAkt、肝细胞核因子1β、缺氧诱导因子1α、p65和诱导型一氧化氮合酶的表达上有显著差异。
子宫内膜异位症相关OEMCa和OCCCa肿瘤发生早期阶段可能存在不同的分子事件。
共0条评论